doxorubicin
Selected indexed studies
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. (Lancet Oncol, 2022) [PMID:35835135]
- An overview of doxorubicin formulations in cancer therapy. (J Cancer Res Ther, 2014) [PMID:25579518]
- A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. (Drug Deliv Transl Res, 2025) [PMID:38884850]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. (2022) pubmed
- An overview of doxorubicin formulations in cancer therapy. (2014) pubmed
- A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. (2025) pubmed
- Liposomal doxorubicin. (1996) pubmed
- Doxorubicin Action on Mitochondria: Relevance to Osteosarcoma Therapy? (2018) pubmed
- Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies. (2026) pubmed
- Doxorubicin. (1998) pubmed
- Impact of Doxorubicin on Cardiac Function in Dogs: Ejection Fraction Changes and Heart Failure Risk. (2025) pubmed
- Doxorubicin-induced cardiotoxicity. (1995) pubmed
- Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity. (2023) pubmed